The drive towards personalized medicine is seeing pharma move from patient stratification as a ‘nice to have’, to an essential feature of product development. Exemplified by the success of Herceptin, biomarkers promise to transform drug discovery, clinical development and diagnostics in the R&D process. This dynamic market, poised to reach a value of $33.3 billion by 2015, will continue to improve decision-making, clinical trial success rates and translational productivity.

Drawing on advances in genomics, translational medicine and clinical trial design, SMi’s sixth annual Biomarkers Summit held on 16th &17th January 2013 London brings you the latest developments from toxicity testing to compound screening and first-in-man studies to companion diagnostic assays, stay competitive with fresh insights from companies at the cutting edge of biopharmaceutical development. Attending will enable you to:

• Accelerate companion diagnostics development for therapeutic indications

• Validate and deliver biomarkers for patient selection during clinical trials

• Implement sub-grouping in patient segmentation studies

• Utilise revised FDA regulatory guidelines to aid product development

• Optimise reimbursement strategies for diagnostics

• Maximise biomarker identification using epigenetic and metabolomic insights

For more information visit www.smi-online.co.uk/goto/biomarkers-summit17.asp alternatively contact Farhaana Rahman on +44 0 207 827 6186 or email on frahman@smi-online.co.uk

The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk

SMi Group Ltd
2nd Floor South, Harling House
47-51 Great Suffolk Street,
London, SE1 0BS

This release was published on openPR.